Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multicentre clinical trial using quantitative MRI

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 938-947

  Raynauld, J P ^a   Martel Pelletier, J ^a   Bias, P ^b   Laufer, S ^c   Haraoui, B ^a   Choquette, D ^a   Beaulieu, A D ^d   Abram, F ^e   Dorais, M ^f   Vignon, E ^g   Pelletier, J P ^a   Bell, Mary J ^h   Benson, William ^h   Carette, Simon ^h   Maksymowych, Walter P ^h   Shojania, Kamran ^h   Tannenbaum, Hyman ^h   Thorne, Carter ^h   Zummer, Michel ^h  

^a NOTRE DAME HOSPITAL   (Canada)

^b TEVA PHARMACEUTICALS   (Israel)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITÉ LAVAL   (Canada)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

LICOFELONE; NAPROXEN; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARTILAGE; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EVENING DOSAGE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; JOINT CAVITY; KNEE MENISCUS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM;

EID: 67449128722     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.088732     Document Type: Article

References (33)

1. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155 (Pubitemid 37500619)
2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000.
3. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001;44:2539-2547 (Pubitemid 33049332)
4. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-256 (Pubitemid 32120855)
5. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-2123 (Pubitemid 35168220)
6. Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-786 (Pubitemid 40365099)
7. Kahan A, Reginster J-Y, Vignon E. STOPP (STudy on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4&6 sulfate (CS). Abstract. 2006; Available at http://www.ibsa-ch.com/eular-2006-amsterdam- vignon-2.pdf (accessed 25 July 2008).
8. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-2025 (Pubitemid 40994324)
9. Laufer S. Discovery and development of ML 3000. Inflammopharmacology 2001;9:101-112
10. Ding C, Cicuttini F. Licofelone Merckle. IDrugs 2003;6:802-808
11. Cicero AFG, Derosa G, Gaddi A. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging 2005;22:393-403. (Pubitemid 41003069)
12. Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, et al. The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Suppression of collagenase-1 and interleukin- 1beta synthesis. Arthritis Rheum 2001;44:2320-2330
13. Pelletier JP, Boileau C, Boily M, Brunet J, Mineau F, Geng C, et al. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of the expression and the synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K, and aggrecanases. Arthritis Res Ther 2005;7:R1091-102.
14. Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol 2002;29:1308-1320
15. Cicuttini FM, Wluka AE, Stuckey SL. Tibial and femoral cartilage changes in knee osteoarthritis. Ann Rheum Dis 2001;60:977-980 (Pubitemid 32885675)
16. Biswal S, Hastie T, Andriacchi TP, Bergman GA, Dillingham MF, Lang P. Risk factors for progressive cartilage loss in the knee: a longitudinal magnetic resonance imaging study in forty-three patients. Arthritis Rheum 2002;46:2884-2892 (Pubitemid 35315879)
17. Felson DT, McLaughlin S, Goggins J, LaValley MP, Gale ME, Totterman S, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139:330-336 (Pubitemid 38124588)
18. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Labonté F, Beaudoin G, de Guise JA, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004;50:476-487 (Pubitemid 38198832)
19. Hayes CW, Jamadar DA, Welch GW, Jannausch ML, Lachance LL, Capul DC, et al. Osteoarthritis of the knee: comparison of MR imaging findings with radiographic severity measurements and pain in middle-aged women. Radiology 2005;237:998-1007. (Pubitemid 41636393)
20. Hunter DJ, Zhang Y, Niu J, Goggins J, Amin S, LaValley MP, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006;54:1529-1535
21. Pelletier JP, Raynauld JP, Berthiaume MJ, Abram F, Choquette D, Haraoui B, et al. Risk factors associated with the loss of cartilage volume on weight bearing areas in knee osteoarthritis patients assessed by qualitative MRI: A longitudinal study. Arthritis Res Ther 2007;9:R74
22. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 2005;64:556-563 (Pubitemid 40469084)
23. Raynauld J-P, Martel-Pelletier J, Berthiaume M-J, Abram F, Choquette D, Haraoui B, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008;67:683-688 (Pubitemid 351571934)
24. Mazzuca SA, Brandt KD, Katz BP, Ding Y, Lane KA, Buckwalter KA. Risk factors for early radiographic changes of tibiofemoral osteoarthritis. Ann Rheum Dis 2007;66:394-399 (Pubitemid 46579643)
25. Altman RD, Asch E, Bloch DA, Bole G, Borenstein D, Brandt KD, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-1049
26. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-1840 (Pubitemid 19037656)
27. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502.
28. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-662
29. Kauffmann C, Gravel P, Godbout B, Gravel A, Beaudoin G, Raynauld JP, et al. Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model. IEEE Trans Biomed Eng 2003;50:978-988 (Pubitemid 36917438)
30. Vignon E, Piperno M, Le Graverand MP, Mazzuca SA, Brandt KD, Mathieu P, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum 2003;48:378-384 (Pubitemid 36278005)
31. Eckstein F, Cicuttini F, Raynauld JP, Waterton JC, Peterfy C. Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthritis Cartilage 2006;14:A46-75. (Pubitemid 43899398)
32. Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis 2004;63:264-268
33. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006;8:R21.